BioAtla provides clinical program updates, 2023 milestones

BioAtla announced its recent accomplishments for its clinical pipeline and provided upcoming 2023 milestones. Company updates and 2023 milestones will be presented in a fireside chat at 41st Annual J.P. Morgan Healthcare Conference, January 10, 2023. Clinical Program Updates: Phase 2 Trial of Mecbotamab Vedotin in Patients with: AXL-positive NSCLC: Part 1 of the trial ongoing in patients who have previously experienced failure of PD-1/L1, EGFR, or ALK inhibitor therapy; 29 patients enrolled to date; 20 efficacy-evaluable patients; In the non-squamous group, 10 of 18 had monotherapy and 8 of 18 had combination therapy with nivolumab; All CR / PRs observed were in the non-squamous group; 4 PRs were in the monotherapy group; 4 PRs were in the monotherapy PD-1 failure group; 1 CR in combination therapy; Following BA3011 in both monotherapy and in combination with nivolumab in advanced NSCLC patients, the safety profile continues to be differentiated, with no new safety signals observed/ AXL-positive Soft Tissue and Primary Bone Sarcomas: Following FDA feedback to the proposed Phase 2 part 2 of the potentially registrational sarcoma study, protocol for UPS study design, including primary endpoint and size of study, finalized and the study is being initiated; Part 1 of the Phase 2 study: Study is progressing with continued efficacy in UPS with 50.0% PFS at 12 weeks; Study ongoing in patients with liposarcoma, synovial sarcoma, and osteosarcoma with continued, encouraging PFS at 12 weeks; Liposarcoma – 66.7% PFS; Synovial sarcoma – 53.5% PFS; Osteosarcoma – 66.7% PFS; In refractory sarcomas, BA3011 in both monotherapy and in combination with nivolumab is generally well-tolerated with no new safety signals observed. Phase 1/2 Dose-Escalation Trial of CAB-CTLA-4 Across Multiple Solid Tumor Types responsive to CTLA-4: Trial ongoing with two of three cohorts completed without any DLTs or SAEs reported. Expected Timing for Key 2023 Milestones – 1H23: Phase 2 study of mecbotamab vedotin in patients with AXL-positive NSCLC; Initiating preparations for discussions with the FDA regarding the potentially registrational part 2 of the study in AXL-positive NSCLC patients; Submission of Phase 2 part 1 interim data for presentation at ASCO; First patient dosed in Phase 2 part 2 study in AXL-positive UPS patients; Interim data in the Phase 2 part 1 ROR-2 positive NSCLC study; CAB-EpCAM x CAB-CD3 TCE Phase 1 study initiation. 2H23: Phase 2 part 2 of the BA3011 study in NSCLC patients anticipated initiation; Interim data in the Phase 2 part 1 ROR-2 positive melanoma study; Interim data in the Phase 2 part 1 ROR-2 positive SCCHN study; Phase 1 data and Phase 2 initiation in CAB-CTLA-4 study.